Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2‐drug cocktail in patients with MET‐dysregulated advanced solid tumours: A phase I, multicentre, open‐label, single‐sequence drug–drug interaction study

AIMS: Capmatinib, an orally bioavailable, highly potent and selective MET inhibitor, was recently approved to treat adult patients with metastatic nonsmall cell lung cancer with METex14 skipping mutations. The study investigated the effect of capmatinib on the pharmacokinetics of a single oral dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Grande, Enrique, Giovannini, Monica, Marriere, Eddie, Pultar, Philippe, Quinlan, Michelle, Chen, Xinhui, Rahmanzadeh, Gholamreza, Curigliano, Giuseppe, Cui, Xiaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359310/
https://www.ncbi.nlm.nih.gov/pubmed/33300203
http://dx.doi.org/10.1111/bcp.14697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359310/
https://www.ncbi.nlm.nih.gov/pubmed/33300203
http://dx.doi.org/10.1111/bcp.14697

Ejemplares similares